PARP Inhibitors in the Management of Ovarian Cancer

Publication Date: September 23, 2022
Last Updated: January 22, 2024

Treatment

Repeating PARPi

Recommendation 1.0

Repeating PARPi therapy in the treatment of epithelial ovarian cancer (EOC) is NOT recommended at this time. Consideration should be made as to the best time in the life cycle of an individual patient’s EOC in which to use PARPi. Clinical trial participation is encouraged. ( IC , Ins , B , S )
3336

Overview

Title

PARP Inhibitors in the Management of Ovarian Cancer

Authoring Organization